ArticleSeminars in arthritis and rheumatism2019
Arterial lesions in giant cell arteritis: A longitudinal study.
Article in Seminars in arthritis and rheumatism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis.Arthritis research & therapy · 2023Pooled it
- ACR Appropriateness Criteria® Noncerebral Vasculitis.Journal of the American College of Radiology : JACR · 2021Guideline
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.Arthritis care & research · 2021Guideline
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Guideline
- Aortic involvement in relapsing polychondritis: case-based review.Rheumatology international · 2021Pooled it
- Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Vasculitis syndromes: large vessel vasculitides and ANCA-associated vasculitides from a neuroradiologist's perspective.Japanese journal of radiology · 2026Review
- Imaging Findings in Giant Cell Arteritis: Don't Turn a Blind Eye to the Obvious!AJNR. American journal of neuroradiology · 2025Review
- Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years.RMD open · 2024Article
- Ultrasound halo count in the differential diagnosis of atherosclerosis and large vessel giant cell arteritis.Arthritis research & therapy · 2023Article
- Pseudoaneurysm of the brachial artery in an infant due to vaccination: a case report.BMC pediatrics · 2023Article
- Association ofArthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.Clinical and experimental medicine · 2022Review
- Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases.Current rheumatology reports · 2022Review
- Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).Rheumatology international · 2022Article
- [Diagnostics and treatment of giant cell arteritis].Der Nervenarzt · 2022Review
- Self-monitoring of the resting heart rate using a fitness tracker smartwatch application leads to an early diagnosis of large vessel vasculitis.BMJ case reports · 2022Article
- Comparing Semiquantitative and Qualitative Methods of VascularJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Observational
- Identification of Acute Giant Cell Arteritis in Real-World Data Using Administrative Claims-Based Algorithms.ACR open rheumatology · 2021Article
- [Long-term complications, monitoring and interventional treatment of large vessel vasculitis].Zeitschrift fur Rheumatologie · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 13 institutions in 2 countries.
Funding
Abstract
objectivesTo evaluate large-vessel (LV) abnormalities on serial imaging in patients with giant cell arteritis (GCA) and discern predictors of new lesions.
methodsClinical and imaging data from patients with GCA (including subjects diagnosed by LV imaging) enrolled in a prospective, multicenter, longitudinal study and/or a randomized clinical trial were included. New arterial lesions were defined as a lesion in a previously unaffected artery.
resultsThe study included 187 patients with GCA, 146 (78%) female, mean (±SD) age at diagnosis 68.5 ± 8.5 years; 39% diagnosed by LV imaging. At least one arterial lesion was present in 123 (66%) on the first study. The most frequently affected arteries were subclavian (42%), axillary (32%), and thoracic aorta (20%). In 106 patients (57%) with serial imaging, new arterial lesions were noted in 41 patients (39%), all of whom had a baseline abnormality, over a mean (±SD) follow-up of 4.39 (2.22) years. New abnormalities were observed in 33% patients by year 2; clinical features of active disease were present at only 50% of these cases. There were no differences in age, sex, temporal artery biopsy positivity, or disease activity in patients with or without new lesions.
conclusionsIn this cohort of patients with GCA, LV abnormalities on first imaging were common. Development of new arterial lesions occurred in patients with arterial abnormalities at first imaging, often in the absence of symptoms of active disease. Arterial imaging should be considered in all patients with GCA at diagnosis and serial imaging at least in patients with baseline abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.